SW
TCRT icon

SkyOak Wealth’s Alaunos Therapeutics TCRT Stock Holding History

SkyOak Wealth’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-563
Closed -$154K – 258
2021
Q3 		$154K Hold
563
– – 0.04% 223
2021
Q2 		$223K Sell
563
-9
-2% -$4.2K 0.06% 211
2021
Q1 		$301K Sell
572
-36
-6% -$22.4K 0.08% 169
2020
Q4 		$230K Buy
+608
New +$242K 0.07% 190

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SkyOak Wealth's TCRT Position: Q4 2021 in Review

SkyOak Wealth sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 563 shares — an estimated $154K sold.

SkyOak Wealth first reported a position in TCRT in Q4 2020 and held it in 4 quarters. The position peaked at $301K in Q1 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • SkyOak Wealth reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SkyOak Wealth sold 563 Alaunos Therapeutics shares in Q4 2021, an estimated $154K.
  • SkyOak Wealth first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 4 quarters.
  • SkyOak Wealth's Alaunos Therapeutics position peaked at $301K in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on SkyOak Wealth's 13F filing for Q4 2021, filed 24 Jan 2022.